Once-Daily Extended-Release Versus Twice-Daily Standard-Release Tacrolimus in Kidney Transplant Recipients: A Systematic Review

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Transplantation

• Publication date

  2013-05-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/TP.0b013e318284c15bPMID 23542469
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The perspectives of kidney transplant recipients on medicine taking: a systematic review of qualitative studies.

  2011cited by this paper
• The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials

  2011cited by this paper
• Pharmacokinetic properties of a once-daily formulation of tacrolimus in patients with renal transplantation

  2011cited by this paper
• Efficacy and Safety of Conversion from Twice‐daily to Once‐daily Tacrolimus in a Large Cohort of Stable Kidney Transplant Recipients

  2011cited by this paper
• Conversion From Prograf to Advagraf Among Kidney Transplant Recipients Results in Sustained Decrease in Tacrolimus Exposure

  2011cited by this paper
• Once daily tacrolimus formulation: monitoring of plasma levels, graft function, and cardiovascular risk factors.

  2010cited by this paper
• Extended-release tacrolimus therapy in de novo kidney transplant recipients: single-center experience.

  2010cited by this paper
• Pharmacokinetics of once- versus twice-daily tacrolimus formulations in kidney transplant patients receiving expanded criteria deceased donor organs: a single-center, randomized study.

  2010cited by this paper
• Reduced C0 Concentrations and Increased Dose Requirements in Renal Allograft Recipients Converted to the Novel Once-Daily Tacrolimus Formulation

  2010cited by this paper
• Improvement of graft function after conversion to once daily tacrolimus of stable kidney transplant patients.

  2010cited by this paper
• Tacrolimus Once Daily (ADVAGRAF) Versus Twice Daily (PROGRAF) in De Novo Renal Transplantation: A Randomized Phase III Study

  2010influential reference
• Three-Month Experience With Tacrolimus Once-Daily Regimen in Stable Renal Allografts

  2009cited by this paper
• De novo kidney transplant recipients need higher doses of Advagraf compared with Prograf to get therapeutic levels.

  2009cited by this paper
• Conversion to tacrolimus extended-release formulation: short-term clinical results.

  2009cited by this paper
• Quantitative Patterns of Azathioprine Adherence After Renal Transplantation

  2009cited by this paper
• Three-month experience with tacrolimus once-daily regimen in stable renal allografts.

  2009cited by this paper
• Immunosuppressant Therapy Adherence and Graft Failure Among Pediatric Renal Transplant Recipients

  2009cited by this paper
• Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement

  2009cited by this paper
• Pharmacokinetics for Once‐ Versus Twice‐Daily Tacrolimus Formulations in De Novo Kidney Transplantation: A Randomized, Open‐Label Trial

  2009cited by this paper
• Transplant Outcomes and Economic Costs Associated with Patient Noncompliance to Immunosuppression

  2009cited by this paper
• One‐Year Results with Extended‐Release Tacrolimus/MMF, Tacrolimus/MMF and Cyclosporine/MMF in De Novo Kidney Transplant Recipients

  2007influential reference
• Tools for assessing quality and susceptibility to bias in observational studies in epidemiology: a systematic review and annotated bibliography.

  2007cited by this paper
• Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies

  2007cited by this paper
• Two years postconversion from a prograf-based regimen to a once-daily tacrolimus extended-release formulation in stable kidney transplant recipients.

  2007cited by this paper
• The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.

  2007cited by this paper
• Immunosuppression: Evolution in Practice and Trends, 1994–2004

  2006cited by this paper
• Modified-Release Tacrolimus

  2006cited by this paper
• Immunosuppression: evolution in practice and trends, 1993–2003

  2005cited by this paper
• Pharmacokinetics of Tacrolimus in Kidney Transplant Recipients: Twice Daily Versus Once Daily Dosing

  2004cited by this paper
• Modified release tacrolimus.

  2004cited by this paper
• Prospective Study on Late Consequences of Subclinical Non‐Compliance with Immunosuppressive Therapy in Renal Transplant Patients

  2004cited by this paper
• Pharmaceutical industry sponsorship and research outcome and quality: systematic review

  2003cited by this paper
• Noncompliance as a cause of renal graft loss.

  2002cited by this paper
• Quantifying heterogeneity in a meta‐analysis

  2002cited by this paper
• A systematic review of the associations between dose regimens and medication compliance.

  2001cited by this paper
• Trim and Fill: A Simple Funnel‐Plot–Based Method of Testing and Adjusting for Publication Bias in Meta‐Analysis

  2000cited by this paper
• Operating characteristics of a rank correlation test for publication bias.

  1994cited by this paper
• Publication bias in clinical research.

  1991cited by this paper
• Patient noncompliance: a major cause of late graft failure in cyclosporine-treated renal transplants.

  1988cited by this paper
• Meta-analysis in clinical trials.

  1986cited by this paper

• The importance of staying within range: associations between tacrolimus intrapatient variability and kidney transplant outcomes

  2026cites this paper
• Efficacy and safety of once-daily prolonged-release tacrolimus versus twice-daily tacrolimus in kidney transplant recipients: A meta-analysis and trial sequential analysis

  2023cites this paper
• Evaluation of limited-sampling strategies to calculate AUC(0–24) and the role of CYP3A5 in Chilean pediatric kidney recipients using extended-release tacrolimus

  2023cites this paper
• Tacrolimus phóng thích kéo dài sử dụng trong ghép thận

  2022cites this paper
• Comparative effectiveness and safety of pharmaceuticals assessed in observational studies compared with randomized controlled trials

  2021cites this paper
• Outcomes of liver transplantation for nonalcoholic steatohepatitis-associated hepatocellular carcinoma.

  2021cites this paper
• Efficacy and Safety of Tacrolimus-Based Maintenance Regimens in De Novo Kidney Transplant Recipients: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials

  2021cites this paper
• Age and sex determine conversion from immediate‐release to extended‐release tacrolimus in a multi‐center cohort of Canadian pediatric renal transplant recipients

  2020cites this paper
• THIRTY YEARS OF TACROLIMUS IN CLINICAL PRACTICE.

  2020cites this paper
• Once-daily prolonged-release tacrolimus versus twice-daily tacrolimus in liver transplantation.

  2019cites this paper
• Immunosuppression for Lung Transplantation: Current and Future

  2018cites this paper
• Extended release versus immediate release tacrolimus in kidney transplant recipients: a systematic review and meta-analysis

  2018cites this paper
• Intervention of Online Percent Coefficient of Variation Reporting System Reduces the Variability of Tacrolimus Trough Concentration in Kidney Transplant Recipients.

  2018cites this paper
• CYP3A5 polymorphisms in renal transplant recipients: influence on tacrolimus treatment

  2018cites this paper
• Maintenance Immunosuppression in Kidney Transplantation

  2017cites this paper
• Clinical Evaluation of Modified Release and Immediate Release Tacrolimus Formulations

  2017cites this paper
• Emerging drugs for prevention of T-cell mediated rejection in liver and kidney transplantation

  2017cites this paper
• Prograf produces more benefits for CYP3A5 low expression patients in early stage after kidney transplantation.

  2017cites this paper
• Tacrolimus Extended Release could be an Alternative to the use of Cyclosporine after Allogeneic HSCT in case of Renal Impairment due to Cyclosporine: A Prospective pilot study from two centers in France

  2017cites this paper
• Pharmacokinetic study of once-daily formulation of tacrolimus (Advagraf) in stable Chinese kidney transplant recipients

  2016cites this paper
• Immunosuppressive Medications.

  2016cites this paper
• Pharmacokinetics of prolonged‐release tacrolimus and implications for use in solid organ transplant recipients

  2016cites this paper
• Immunosuppressive therapy for kidney transplantation in adults: a systematic review and economic model.

  2016cites this paper
• The role of CYP3A5 polymorphism and dose adjustments following conversion of twice-daily to once-daily tacrolimus in renal transplant recipients

  2016cites this paper
• Higher Variability of Tacrolimus Trough Level Increases Risk of Acute Rejection in Kidney Transplant Recipients.

  2016cites this paper
• Immunosuppression and Results in Renal Transplantation

  2016cites this paper
• Immunosuppressive therapy for kidney transplantation in children and adolescents: systematic review and economic evaluation.

  2016cites this paper
• Conversion From Twice-Daily to Once-Daily Tacrolimus Does Not Reduce Intrapatient Variability in Tacrolimus Exposure

  2015cites this paper
• Optimizing immunosuppressive therapy after renal transplantation

  2015cites this paper
• Immunosuppression and Post-transplant Hyperglycemia.

  2015cites this paper
• Tacrolimus Prolonged Release (Envarsus®): A Review of Its Use in Kidney and Liver Transplant Recipients

  2015cites this paper
• Polymer‐Based Augmentation of Immunosuppressive Formulations: Application of Polymer Technology in Transplant Medicine

  2015cites this paper
• Advances in pharmacotherapy to treat kidney transplant rejection

  2015cites this paper
• Limited sampling strategy for prolonged-release tacrolimus in renal transplant patients by use of the dried blood spot technique

  2015cites this paper
• Delayed trough level measurement with the use of prolonged‐release tacrolimus

  2015cites this paper
• Extended release once a day tacrolimus

  2015influential citation
• Extended-Release Tacrolimus: A Review of Its Use in De Novo Kidney Transplantation

  2014influential citation
• Superior rejection profile during the first 24 months after heart transplantation under tacrolimus as baseline immunosuppressive regimen

  2014cites this paper
• A prospective cohort conversion study of twice-daily to once-daily extended-release tacrolimus: role of ethnicity

  2014cites this paper
• Protocol biopsy findings in living donor kidney transplant patients treated with once-daily or twice-daily tacrolimus formulation.

  2014cites this paper
• Update on the clinical utility of once-daily tacrolimus in the management of transplantation

  2014cites this paper
• A randomized cross-over comparison of short-term exposure of once-daily extended release tacrolimus and twice-daily tacrolimus on renal function in healthy volunteers

  2014cites this paper
• Long-Term Follow-Up of a Phase III Clinical Trial Comparing Tacrolimus Extended-Release/MMF, Tacrolimus/MMF, and Cyclosporine/MMF in De Novo Kidney Transplant Recipients

  2014cites this paper
• Prevention of organ rejection in renal and liver transplantation with extended release tacrolimus

  2014cites this paper
• Harnessing Regulatory T Cells for Clinical Use in Transplantation: The End of the Beginning

  2014cites this paper
• Treatment satisfaction in renal transplant patients taking tacrolimus once daily.

  2013cites this paper
• Current trends in immunosuppression following organ transplantation in children

  2013cites this paper
• Significant reduction of Tacrolimus trough level after conversion from twice daily Prograf to once daily Advagraf in Chinese renal transplant recipients with or without concomitant diltiazem treatment

  2013cites this paper
• Once– versus twice–daily tacrolimus: are the formulations equivalent?

  2013cites this paper